Drug Information

General Information
Drug ID
DR00176
Drug Name
Ribavirin
Synonyms
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; 1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide; AA-504/07617051; C-Virin; Copegus; Copegus (TN); Cotronak; DRG-0028; Drug: Ribavirin; ICN-1229; KS-1104; R 9644; R-964; RBV; RG-964; RTC; RTCA; Ravanex; Rebetol; Rebetol (TN); Rebetron; Rebretron; Ribacine; Ribamide; Ribamidil; Ribamidyl; Ribasphere; Ribasphere (TN); Ribav; Ribavirin (JAN/USP/INN); Ribavirin Capsules; Ribavirin [USAN:INN]; Ribavirina; Ribavirina [INN-Spanish]; Ribavirine; Ribavirine [INN-French]; Ribavirinum; Ribavirinum [INN-Latin]; Ribovirin; Ro 20-9963/000; Ro-20-9963; SCH 18908; Tribavirin; Varazid; Vilona; Vilona (TN); Viramid; Viramide; Virazid; Virazide; Virazole; Virazole (Ribavirin) Inhalation Solution; Virazole (TN)
Drug Type
Small molecular drug
Indication Hepatitis C virus infection [ICD11: 1E50.2, 1E51.1] Approved [1]
Therapeutic Class
Antiviral Agents
Structure
3D MOL 2D MOL
Formula
C8H12N4O5
Canonical SMILES
C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N
InChI
InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
InChIKey
IWUCXVSUMQZMFG-AFCXAGJDSA-N
CAS Number
CAS 36791-04-5
Pharmaceutical Properties Molecular Weight 244.2 Topological Polar Surface Area 144
Heavy Atom Count 17 Rotatable Bond Count 3
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 7
XLogP
-1.8
PubChem CID
37542
PubChem SID
11335957 , 11361196 , 11364740 , 11367302 , 11369864 , 11372951 , 11374942 , 11378029 , 11462168 , 11491691 , 11493066 , 11495640 , 11528313 , 12059582 , 14798456 , 15122005 , 17389529 , 17405619 , 24278685 , 25621753 , 26538475 , 26612558 , 26679740 , 34678832 , 46505883 , 47291173 , 47365228 , 47440296 , 47515344 , 47589035 , 47885447 , 47885448 , 48035157 , 48416516 , 48424047 , 48425596 , 48631153 , 49699015 , 50105410 , 50105411 , 50105412 , 50105413 , 50474786 , 53778169 , 595938 , 7847489 , 7980513 , 8139972 , 8150084 , 8175073
ChEBI ID
CHEBI:63580
TTD Drug ID
D0H3WI
DT(s) Transporting This Drug CNT2 Transporter Info Concentrative nucleoside transporter 2 Substrate [2]
CNT3 Transporter Info Concentrative Na(+)-nucleoside cotransporter 3 Substrate [3]
ENT1 Transporter Info Equilibrative nucleoside transporter 1 Substrate [4]
PEPT1 Transporter Info Peptide transporter 1 Substrate [5]
Drug-Transporter Activity Data
Drug-Transporter Activity Data CNT3 Transporter Info Km = 28.2 microM Xenopus oocytes-hCNT3 and hENT1 [3]
References
1 Ribavirin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Identification and functional analysis of variants in the human concentrative nucleoside transporter 2, hCNT2 (SLC28A2) in Chinese, Malays and Indians. Pharmacogenet Genomics. 2007 Sep;17(9):783-6.
3 Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes. Biophys Chem. 2010 Mar;147(1-2):59-65.
4 Effects of dipyridamole coadministration on the pharmacokinetics of ribavirin in healthy volunteers. Drug Metab Pharmacokinet. 2013;28(5):406-10.
5 Transport of levovirin prodrugs in the human intestinal Caco-2 cell line. J Pharm Sci. 2006 Jun;95(6):1318-25.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.